Affymetrix and Reveal Biosciences Partner to Offer RNA ISH Tissue Staining, Imaging, and Image Analysis Services
December 02 2015 - 6:30AM
Business Wire
Affymetrix Inc. (NASDAQ:AFFX) and Reveal Biosciences LLC, an
advanced tissue technologies company, today announced a partnership
agreement through which Reveal will use Affymetrix ViewRNA® ISH
products for tissue samples to provide RNA in situ hybridization
(ISH) staining, imaging, and quantification services using the
company’s proprietary image analysis software, ImageDx™.
“RNA in situ hybridization is fast becoming the method of choice
for researchers wanting to validate established and novel
biomarkers for translational and clinical research,” said Guy
Afseth, marketing director for Affymetrix’ oncology portfolio. With
Affymetrix’ ViewRNA ISH portfolio for tissue samples, researchers
can rapidly design assays for virtually any mRNA transcript or long
noncoding RNA in any tissue type. ViewRNA assays utilize branched
DNA signal amplification technology to achieve unparalleled
sensitivity and specificity, enabling the visualization of targets
at the single-molecule level within the context of the tissue
morphology.
“We are thrilled to partner with Affymetrix to provide
high-quality services using ViewRNA products. Our scientific
expertise, combined with high-resolution imaging and our
proprietary image analysis software, ImageDx™, form a
powerful platform for the localization and quantification of mRNA
in tissue samples,” said Dr. Claire Weston, CEO and founder of
Reveal Biosciences. “This highly sensitive technology is changing
the face of mRNA biomarker screening and analysis for translational
research and diagnostics.”
About Reveal Biosciences
Reveal Biosciences is a leading provider of advanced tissue
technology services and tissue-based research. The company’s
portfolio includes in situ hybridization (ISH),
immunohistochemistry (IHC), immunofluorescence (IF), and histology.
Reveal enhances these services with proprietary technologies for
NGPx™ Next Generation Pathology, multiplexing, whole-slide
imaging, and ImageDx™ image analysis software as a service.
For more information about Reveal Biosciences, please visit:
http://www.revealbio.com.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of benchtop research into
clinical and routine use for human health and wellness. Affymetrix
provides leadership and support, partnering with customers in
pharmaceutical, diagnostic, and biotechnology companies as well as
leading academic, government, and non-profit research institutes in
their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
94,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, San
Diego, Vienna and Singapore. Affymetrix has about 1,100 employees
and maintains sales and distribution operations worldwide. For more
information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2014, and other SEC reports for subsequent
quarterly periods.
PLEASE NOTE: Affymetrix, the Affymetrix logo, and ViewRNA
trademarks are the property of Affymetrix, Inc. All other
trademarks are the property of their respective owners.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151202005041/en/
AffymetrixMedia ContactMindy
Lee-Olsen, 408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comInvestor ContactDoug Farrell, 408-731-5285Vice
President, Investor Relationsdoug_farrell@affymetrix.comorReveal
BiosciencesMedia and Investor
ContactAmi Lau, 858-274-3663External
Relationsalau@revealbio.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024